Martina Benešová-Schäfer: Science That Is Changing the Possibilities of Cancer Treatment

Martina Benešová-Schäfer is a radiochemist whose work has helped advance modern nuclear medicine. She played a key role in the development of PSMA-617, a molecule designed for the targeted diagnosis and treatment of prostate cancer. Its development represents an important step toward more precise approaches to cancer care.

The molecule specifically targets prostate-specific membrane antigen (PSMA), which is abundantly present on prostate cancer cells. When combined with radioactive lutetium-177, it enables radiation to be delivered more selectively to cancer cells, helping limit exposure to surrounding healthy tissue. This targeted approach forms the basis of a new generation of radioligand therapies in oncology.

Research surrounding the molecule culminated in the development of lutetium-177 PSMA-targeted therapy, while the radiopharmaceutical is now known under the trade name Pluvicto®. The therapy demonstrated significant clinical benefit in the VISION trial, improving both overall survival and radiographic progression-free survival compared with standard care alone.

For her contributions to the invention and preclinical development of the molecule, Benešová-Schäfer was honored with the Czech Inventor Award. Her collaborative efforts have also received recognition through awards such as the Image of the Year Award and the Berson-Yalow Award. These honors reflect not only individual achievement but also the collaborative nature of scientific research and medical innovation.

Her work demonstrates how radiochemistry, molecular biology and medicine can converge to create new approaches to cancer care. By taking a molecular concept from the laboratory and helping develop it into a viable treatment option, the research illustrates how scientific discovery can translate into tangible benefits for patients with advanced prostate cancer.

The broader advances in targeted radioligand therapy also point toward a future in which cancer treatment can become increasingly precise and personalized. As researchers continue to explore new molecular targets and refine existing therapies, radiochemistry is becoming an increasingly important part of the development of modern oncology.

The story behind this research shows that the true value of a scientific discovery lies not only in the laboratory, but in the moment when it reaches the patient. Her work demonstrates how the combination of radiochemistry, medicine and innovation can reshape the way cancer is treated. What began as a research project has become part of modern oncology, with targeted radioligand therapy now available to eligible patients.

And that is where its greatest significance lies: turning scientific knowledge into solutions that can make a real difference to human lives.